As artificial intelligence reshapes life sciences research, two leading Elsevier Gold Open Access peer-reviewed journals, SLAS Discovery and SLAS Technology, invite contributions to Special Issues exploring how AI, automation and self-driving laboratories are transforming drug discovery. Submissions are accepted until 15 December 2026.
Matisse raises €14M for Phase 2 sepsis trial
Latest NewsDutch biotech Matisse Pharmaceuticals has raised €14 million in a Series A financing to advance isupartob sodium through Phase 2 development in sepsis.
Novartis drops TREM2 antibody in ALS after Phase 2 miss
Latest NewsNovartis has stopped developing its TREM2 antibody VHB937 (lifonebart) in amyotrophic lateral sclerosis (ALS) after the 251-patient Phase 2 ASTRALS trial missed its primary and secondary endpoints, and shortly after Axoltis Pharma suffered a similar Phase 2 setback.
Novartis pays $125M for Sironax brain delivery platform
Latest NewsNovartis is paying $125 million (€106 million) to acquire global rights to Sironax’s brain delivery platform, exercising an option it secured from the U.S.-Chinese biotech in July 2025. Sironax will retain rights to use the technology for selected assets.
Orbis lands $1.4B macrocycle partnership with Novo
Latest NewsNovo has entered a collaboration and licensing agreement with Danish biotech Orbis Medicines worth up to $1.4 billion (€1.2 billion) to discover oral macrocycle drugs for cardiometabolic diseases. Novo will also make an undisclosed strategic investment in Orbis.
Roche taps Dualitas in $1B bispecific deal
Latest NewsRoche will pay Dualitas Therapeutics $36.5 million upfront in a research collaboration that could be worth up to $1 billion to discover bispecific antibodies for immune and inflammatory diseases.
SLAS Journals Spotlight AI in Drug Discovery
Sponsored PublicationsAs artificial intelligence reshapes life sciences research, two leading Elsevier Gold Open Access peer-reviewed journals, SLAS Discovery and SLAS Technology, invite contributions to Special Issues exploring how AI, automation and self-driving laboratories are transforming drug discovery. Submissions are accepted until 15 December 2026.
Sensorion files confidentially for potential U.S. IPO
Latest NewsThe French hearing-loss biotech has taken the first formal step toward a potential U.S. listing, as it advances its remaining gene therapy program into the clinic.
The Strüngmann legacy, passed on
Background, Latest NewsThomas and Andreas Strüngmann have spent decades building pharmaceutical companies and backing biotech entrepreneurs, most famously BioNTech. Now, as a new generation takes a larger role in their family office, an award bearing their name is turning that investment philosophy into a search for Europe’s next biotech builders.
3PBIOVIAN appoints Ponchi Kantt-Neaz as Global Executive Business Director
slider, Sponsored PublicationsThe appointment of Ponchi marking an important milestone in the company’s global commercial strategy and further strengthening its commercial leadership as the company continues to expand its presence in the global CDMO market.
ResoTher heart data clear acquisition hurdle, set up 200-patient trial
Latest NewsDanish biotech ResoTher Pharma’s heart attack drug RTP-026 was well tolerated and showed early efficacy signals in a 66-patient Phase 2a trial, according to results announced Sept. 14 that clear a key condition for Swedish-listed Hunter Capital RTO 1’s planned reverse acquisition of the company.